GLAND

- Gland Pharma Limited has issued a notice of Postal Ballot dated October 01, 2026, seeking approval from members for the appointment of Mr. Xingli Wang (DIN: 18926) as a Non-Executive & Non-Independent Director of the company. - The remote e-voting period commences on Wednesday, October 07, 2026 (09:00 AM IST) and ends on Thursday, November 05, 2026 (05:00 PM IST). - The cut-off date for determining voting rights is October 01, 2026, and the voting results will be announced on or before November 09, 2026.

- Gland Pharma Limited approved an investment of USD 21 million in its wholly-owned subsidiary, Gland Pharma USA Inc. - Gland Pharma USA Inc. will utilize these funds to acquire a 60% stake in Novelstar Pharma Inc. for USD 21 million by October 31, 2026. - Mr. Wenjie Zhang resigned as Non-Executive & Non-Independent Director effective October 01, 2026. - Mr. Xingli Wang was appointed as an Additional Director (Non-Executive & Non-Independent Director) effective October 01, 2026.

- Gland Pharma announced an investment of USD 21 million in its step-down subsidiary, Gland Pharma USA Inc., to subscribe to a 60% equity stake in Novelstar Pharma Inc. by October 31, 2026. - Mr. Wenjie Zhang resigned as Non-Executive & Non-Independent Director effective October 01, 2026. - Mr. Xingli Wang was appointed as an Additional Director (Non-Executive & Non-Independent Director) effective October 01, 2026.

- Board approved acquisition of 100% equity of Gland Pharma USA Inc. (a step-down subsidiary) for USD 5,01,208. - Purpose is to streamline corporate structure; no material impact on business. - Expected completion by October 31, 2026.

- Gland Pharma Limited's Board approved the acquisition of 100% equity share capital of Gland Pharma USA Inc. (Gland US) from its step-down subsidiary, Gland Pharma International Pte. Ltd. - This internal acquisition, costing USD 5,01,208/-, aims to streamline the corporate structure. - Gland US, involved in pharmaceutical marketing and distribution in the USA, will become a direct wholly-owned subsidiary by October 31, 2026. - The company stated no material impact on business or operations.

- Gland Pharma allotted 42,393 equity shares to 35 employees under ESOP 2025 and 1,800 equity shares to 1 employee under ESOP 2019. The ESOP 2019 scheme is formally closed. Post-allotment, issued share capital increased to 165,010,854 equity shares of Re. 1/- each.

- Gland Pharma Limited granted 5,90,249 Employee Stock Options under its ESOP 2025 scheme to 124 employees. - Options are granted at two exercise prices: ₹1,461.15 for 3,89,564 options and ₹1 for 2,00,685 options. - Vesting occurs over three years: 34% (Year 1), 33% (Year 2), and 33% (Year 3) from September 13, 2026.

- Gland Pharma received notices from NSE and BSE regarding a 34-day technical non-compliance with Regulation 17(1A) for a Non-Executive Director's appointment. - The company was levied a fine of ₹70,000/- each by both exchanges. - The Board advised strengthening internal compliance processes, and the company proactively paid the entire fine amount at one time.

- Investor Meetings Scheduled: - September 16, 2026: One-on-One meeting with East Bridge Capital. - September 17, 2026: One-on-One meeting with IIFL Capital. - September 17, 2026: One-on-One meeting with Antique Broking. - September 25, 2026: Group meeting arranged by Nomura.

- Concall Schedule - Concall Date: September 11, 2026 - Meeting Type: One-on-One Meeting with DSP Mutual Fund

- Concall Schedule - Concall Date: September 09, 2026 - Investor/Analyst/Fund: Kotak Mutual Fund - Type of Meeting: One-on-One Meeting

- USFDA conducted a routine Good Manufacturing Practice (GMP) Inspection at Gland Pharma's VSEZ Sterile Oncology Formulations Facility and API Facility, Visakhapatnam. - The inspection concluded with ZERO (0) Form 483 Observations.

- Gland Pharma Limited has scheduled a series of analyst and institutional investor meetings from September 03 to September 24, 2026. - Meetings include one-on-one and group interactions with various funds like Carnelian Capital, WCM Investment (arranged by Jefferies), LIC MF, BofA Securities, and JP Morgan.

- Schedule of Analyst / Institutional Investor Meetings - August 26, 2026: One-on-one meeting with Nomura. - August 27, 2026: One-on-one meeting with HDFC MF (arranged by Investec).

- Q1 FY27 Consolidated Revenue ₹18,003 million (▲20% YoY), Adjusted EBITDA ₹5,102 million (margin 28% vs 25% YoY), PAT ₹3,170 million (▲47% YoY). - CDMO and B2B segments each contributed 50% to total revenues, with healthy growth (CDMO ▲20% YoY, B2B ▲19% YoY). U.S. revenue grew by 32% YoY; Europe & other regulatory markets grew by 11% YoY. - Secured a strategic manufacturing and supply agreement for sterilized injectables (55 SKUs), with potential revenue of USD90-100 million from CY2029. - Entered strategic collaboration with Neuland Laboratories for sterile APIs for microparticle depot products (NDDS project), with development by '28, commercialization in '29, and revenue potential of USD25-30 million. - Commenced INR2,000 crores Capex program, planning to spend ₹550 crores in FY27, to support growth and CDMO demand. New ampoule line at Cenexi by early 2027 to add ~30 million ampoules annual capacity. - Expects 15% constant currency growth for FY27, potentially higher, and "around 20% growth" over the next 4 years. - Targeting 30% consolidated EBITDA margin in the near term, aiming for 35% in the midterm to long term. Cenexi is targeting double-digit EBITDA margins by year-end FY27 (currently 4%).

- Gland Pharma Limited announced the appointment of Mr. Deepak Sapra as the new Chief Executive Officer (CEO). - He will join the company with effect from November 16, 2026. - Mr. Sapra brings 27 years of executive experience, including over 23 years in the pharmaceutical industry, and was previously CEO - API and Services at Dr. Reddy's Laboratories.

- The Earnings Call for the quarter ended June 30, 2026, held on August 10, 2026, at 18:30 Hrs. (IST), has its audio recording uploaded on the company's website. - Weblink: https://glandpharma.com/images/Q1_FY27.mp3

- Investor/Analyst Meetings Schedule - August 13, 2026: One-on-One Meeting with UTI MF (arranged by ICICI Securities) - August 17, 2026: One-on-One & Group Meetings at Motilal Oswal Investor Conference - August 20, 2026: One-on-One Meeting with Ashmore (arranged by ICICI Securities)

- Q1 FY27 Consolidated Revenue ₹1,800.3Cr vs ₹1,505.6Cr (▲20% YoY) - EBITDA ₹493.0Cr vs ₹367.8Cr (▲34% YoY) - PAT ₹317.0Cr vs ₹215.5Cr (▲47% YoY) - EBITDA Margin 27% vs 24% (▲300bps)

- Q1 FY27 Consolidated Revenue ₹1,800.3Cr vs ₹1,505.6Cr (▲20% YoY) - EBITDA ₹493Cr vs ₹367.8Cr (▲34% YoY) - PAT ₹317Cr vs ₹215.5Cr (▲47% YoY) - EBITDA Margin 27% vs 24% (▲300bps)

- Q1 FY27 Consolidated Revenue ₹1,800.3 Cr vs ₹1,505.6 Cr (▲20% YoY) - EBITDA ₹493 Cr vs ₹367.8 Cr (▲34% YoY) - PAT ₹317 Cr vs ₹215.5 Cr (▲47% YoY) - EBITDA Margin 27% vs 24% (▲300bps)

- Gland Pharma announced a strategic CDMO partnership with a global pharmaceutical company for the Technology Transfer, Manufacturing and Supply of a portfolio of sterile injectable products for global markets. - The agreement covers 55 SKUs (oncology and non-oncology products) across three sites, with potential for more products. - Annualized revenue potential is expected to be approximately USD 90-100 million once all products are commercialized. - Revenue generation is anticipated from calendar year 2029.

- Order Win: Gland Pharma Limited entered into a Strategic CDMO Partnership with a Global Pharmaceutical Company for the Technology Transfer, Manufacturing, and Supply of a portfolio of sterile injectable products for global markets. - Order Value: Annualized revenue potential is expected to be approximately USD 90-100 million once all products are commercialized. - Completion Timeline: Revenues are anticipated to commence from calendar year 2029.

- Gland Pharma and Neuland Laboratories announced a strategic CDMO partnership for sterile API manufacturing. - Gland Pharma will establish a new sterile manufacturing suite at its JNPC facility in Visakhapatnam. - The new suite will add approximately 1400 kg of annual capacity, enhancing supply resilience.

- The 48th Annual General Meeting (AGM) of Gland Pharma Limited is scheduled for August 25, 2026, at 11:00 A.M (IST) via Video Conferencing/OAVM. - The Annual Report for FY 2025-26 is accessible via a provided web-link and QR Code. - A final dividend of ₹20/- per share for FY2025-26 has been declared, with a record date of August 11, 2026, and payment by September 24, 2026. - E-voting will commence on August 22, 2026, at 9:00 A.M (IST) and conclude on August 24, 2026, at 5:00 P.M (IST).

- Submitted the Business Responsibility and Sustainability Report (BRSR) for the Financial Year ended March 31, 2026. - Filed as per Regulation 34(2)(f) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. - The BRSR also forms part of the Annual Report for FY 2025-26 and is accessible on the company's website.

- The 48th Annual General Meeting (AGM) will be held on Tuesday, August 25, 2026, at 11:00 A.M (IST) via VC/OAVM. - Key agendas include the adoption of audited Standalone and Consolidated Financial Statements for FY ended March 31, 2026. - A final dividend of ₹20/- per equity share for the financial year ended March 31, 2026, will be declared, with a record date of August 11, 2026. - Reappointment of Mr. Wenjie Zhang and Ms. Wei Huang as Directors, liable to retire by rotation, will be considered. - E-voting will be available from August 22, 2026, to August 24, 2026, with the cut-off date for e-voting being August 18, 2026.

- Gland Pharma allotted 6,979 equity shares on July 30, 2026, upon exercise of Employee Stock Options under its 2025 scheme. - The company's paid-up share capital increased to 164,966,661 equity shares. - Exercise prices varied: 4,606 options at ₹773.30/share and 2,373 options at ₹1/share.

- Gland Pharma Limited approved the grant of 16,790 Employee Stock Options (ESOPs) to 3 employees under the Gland Pharma Employee Stock Option Scheme 2025 on July 30, 2026. - 11,081 options are priced at ₹1258.50 (50% of closing price) and 5,709 options at ₹1 (face value). - The options will vest over three years: 34% on July 30, 2027, 33% on July 30, 2028, and 33% on July 30, 2029.